CTOs on the Move

Boston MicroFluidics

www.bostonmicrofluidics.com

 
Boston Microfluidics (BMF) is dedicated to connecting people to their health by increasing access to diagnostic testing for all people. Our technology is a unique combination of elegant sample processing solutions with an intuitive user interface. We strive to streamline current testing systems with devices that perform complex sample processing steps without the need for trained professionals or specialized laboratory equipment. We also seek to simplify diagnostic tests so that they can be used efficiently at the point of care, or even be available for direct sale to consumers. Above all, BMF works to help provide patients with ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Funding

Boston MicroFluidics raised $17.5M on 08/27/2019

Similar Companies

Columbus Neighborhood Health Center

Columbus Neighborhood Health Center is a Columbus, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Community Partners Behavioral Health and Developmental Services of Strafford County

Community Partners Behavioral Health and Developmental Services of Strafford County is a Dover, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cardinal Analytx Solutions

Cardinal Analytx Solutions brings together distinguished innovators and leaders collaboratively advancing into new territory to substantially address one of the most pressing human and economic challenges of our time.

PerioSciences

PerioSciences antioxidant infused oral gel, toothpaste, and mouth rinse help keep your teeth and gums healthy. Check out our entire line here!

Enterin Inc.

Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.